A carregar...
Delafloxacin: design, development and potential place in therapy
Delafloxacin (DLX) is a new fluoroquinolone pending approval, which has shown a good in vitro and in vivo activity against major pathogens associated with skin and soft tissue infections and community-acquired respiratory tract infections. DLX also shows good activity against a broad spectrum of mic...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5367733/ https://ncbi.nlm.nih.gov/pubmed/28356714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S106071 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|